The effect of para-aortic lymph node metastasis on the resectability of pancreatic cancer
10.3760/cma.j.issn.0529-5815.2019.01.014
- VernacularTitle: 主动脉旁淋巴结转移对胰腺癌可切除性影响的研究进展
- Author:
Hongmei DAI
1
;
Xiafei HONG
1
;
Haiyu PANG
2
;
Wenming WU
1
;
Yupei ZHAO
1
Author Information
1. Department of General Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
2. Central Research Laboratory, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
- Publication Type:Review
- Keywords:
Pancreatic neoplasms;
Surgical procedures, operative;
Para-aortic lymph node;
Lymph node metastasis;
Prognosis
- From:
Chinese Journal of Surgery
2019;57(1):68-71
- CountryChina
- Language:Chinese
-
Abstract:
Pancreatic cancer has poor prognosis and lymph node metastasis is a poor prognostic factor in patients with resectable pancreatic cancer. The metastatic prevalence of para-aortic lymph node (PALN) ranges from 9.1% to 26.5% and it is listed as the distant metastatic group in pancreatic cancer. Nevertheless, it is controversial whether PALN metastasis is the contraindication of surgery in resectable pancreatic cancer for the shortage of level Ⅰ evidence.This study concluded that PALN metastasis indicated poor prognosis in patients with pancreatic cancer, but some patients with PALN metastases could benefit from surgery and their survival could be much improved after the combination of surgery and adjuvant therapy. Therefore, it is not wise to refuse surgery for all pancreatic cancer patients with PALN metastasis and the clinicians can cautiously choose the patients to do surgery. Besides, there are mainly retrospective studies rather than prospective and multicenter studies to explore the prognosis of pancreatic cancer patients with PALN metastasis. Thus, more prospective and multicenter studies are needed to decide whether PALN metastasis is an independent prognostic factor in patients with resectable pancreatic cancer.
